Medicine and Dentistry
Diseases
100%
Overall Survival
99%
Rectum Cancer
86%
Neoplasm
64%
Pancreas Cancer
61%
Neoadjuvant Therapy
59%
Krukenberg Tumor
57%
Pancreas Islet Cell Tumor
57%
Lymph Node
39%
Retrospective Study
39%
Disease Free Survival
38%
BRCA Mutation
34%
Chemoradiotherapy
33%
Postoperative Complication
32%
Colon Carcinoma
31%
Cross Sectional Study
28%
Osteolysis
28%
COVID-19
28%
Diabetes Mellitus
28%
Dysglycemia
28%
Phase II Trials
28%
Stomach Adenocarcinoma
28%
Zoledronic Acid
28%
Clinical Trial
28%
Paclitaxel
28%
Breast Cancer
28%
Thyroid Cancer
28%
Doxorubicin
28%
Biological Marker
28%
Tomography
28%
Postmenopause
28%
Gallium 68
28%
Carboplatin
28%
Letrozole
28%
Tamoxifen
28%
Vemurafenib
28%
Telemedicine
28%
Fluorodeoxyglucose F 18
28%
Esophageal Cancer
28%
Intraperitoneal Chemotherapy
28%
Lymphocytopenia
28%
Pancreas Fistula
28%
Peritoneum Metastasis
28%
Pancreaticoduodenectomy
28%
Pancreas Adenocarcinoma
28%
Treatment Response
28%
Radiation Therapy
28%
Polyethylene Terephthalate
28%
Magnetic Resonance Imaging
28%
Progression Free Survival
23%
Keyphrases
Colorectal Cancer
71%
Overall Survival
70%
Neoadjuvant
61%
Neoadjuvant Therapy
60%
Oncology Patients
57%
FOLFIRINOX
57%
Resectable Pancreatic Cancer
57%
Retrospective Analysis
41%
BRCA mutation
38%
Improved Outcomes
35%
Protective Effect
33%
Chemoradiotherapy
33%
Disease-free Survival
33%
Confidence Interval
32%
Cancer Patients
32%
Postoperative Complications
32%
Complete Response
32%
Pancreatic Neuroendocrine Tumors (pNETs)
31%
5-year Survival
31%
Chemotherapy
30%
Borderline Resectable Pancreatic Cancer
30%
Tumor
29%
Prospective Randomized Trial
28%
Paclitaxel
28%
Cannabis
28%
Bone Loss
28%
Nonfunctional Pancreatic Neuroendocrine Tumor
28%
Type 1 Diabetes Mellitus (T1DM)
28%
68Ga-FAPI
28%
Dysglycemia
28%
Postmenopausal Women
28%
Activating mutation
28%
Zoledronic Acid
28%
Long-term Response
28%
Thyroid Cancer
28%
Oxaliplatin-induced Neuropathy
28%
Metastatic Gastric Cancer
28%
Lymph Node Ratio
28%
Advanced Ovarian Cancer
28%
Locally Advanced Rectal Cancer
28%
Clinical Outcomes
28%
Carboplatin
28%
Microscopic Disease
28%
Clinical Experience
28%
Randomized Phase II Trial
28%
Multi-key Homomorphic Encryption
28%
Progression-free Survival
28%
Undergraduate Medical Students
28%
Rapid Implementation
28%
Patients with Cancer
28%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
62%
Ovary Carcinoma
57%
Neoplasm
50%
Diseases
50%
Postoperative Complication
32%
Retrospective Study
32%
Pancreas Cancer
32%
Diabetes Mellitus
31%
Colon Carcinoma
31%
Paclitaxel
28%
Chemoradiation Therapy
28%
Pancreas Islet Cell Tumor
28%
Oxaliplatin-Induced Peripheral Neuropathy
28%
Rectum Cancer
28%
Zoledronic Acid
28%
Irritable Colon
28%
Thyroid Cancer
28%
Phase II Trials
28%
Tamoxifen
28%
Doxorubicin
28%
Posttraumatic Stress Disorder
28%
Dysglycemia
28%
Vemurafenib
28%
Carboplatin
28%
Letrozole
28%
Breast Cancer
28%
Cannabis
28%
Pancreas Fistula
28%
Peritoneum Metastasis
28%
Pancreas Adenocarcinoma
28%
Intraperitoneal Chemotherapy
28%
Comorbidity
28%
Oxaliplatin
26%
Chemotherapy
21%
Impaired Glucose Tolerance
19%
Disease Free Survival
19%
Prevalence
16%
Neuropathy
14%
Progression Free Survival
13%
Chemotherapy-Induced Peripheral Neuropathy
12%
Carcinoma
11%
Recurrent Disease
10%
Hormone Receptor
9%
Survival Rate
9%
Melanoma
8%
Malignant Neoplasm
7%
Immunogenic Cell Death
6%
Colorectal Carcinoma
6%
Disease Exacerbation
5%
Hair Loss
5%